Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5UUM

Human Mcl-1 in complex with a Bfl-1-specific selected peptide

Summary for 5UUM
Entry DOI10.2210/pdb5uum/pdb
Related5UUK 5UUL 5UUP
DescriptorInduced myeloid leukemia cell differentiation protein Mcl-1, Bfl-1 specific peptide FS2, ZINC ION, ... (5 entities in total)
Functional Keywordsapoptosis regulatory proteins, peptide library, protein binding, protein structure, proto-oncogene, specificity, bcl2a1, bcl2 related protein a1, peptide inhibitor, apoptosis
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains4
Total formula weight41665.83
Authors
Jenson, J.M.,Grant, R.A.,Keating, A.E. (deposition date: 2017-02-17, release date: 2017-06-21, Last modification date: 2024-10-16)
Primary citationJenson, J.M.,Ryan, J.A.,Grant, R.A.,Letai, A.,Keating, A.E.
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1.
Elife, 6:-, 2017
Cited by
PubMed Abstract: Overexpression of anti-apoptotic Bcl-2 family proteins contributes to cancer progression and confers resistance to chemotherapy. Small molecules that target Bcl-2 are used in the clinic to treat leukemia, but tight and selective inhibitors are not available for Bcl-2 paralog Bfl-1. Guided by computational analysis, we designed variants of the native BH3 motif PUMA that are > 150-fold selective for Bfl-1 binding. The designed peptides potently trigger disruption of the mitochondrial outer membrane in cells dependent on Bfl-1, but not in cells dependent on other anti-apoptotic homologs. High-resolution crystal structures show that designed peptide FS2 binds Bfl-1 in a shifted geometry, relative to PUMA and other binding partners, due to a set of epistatic mutations. FS2 modified with an electrophile reacts with a cysteine near the peptide-binding groove to augment specificity. Designed Bfl-1 binders provide reagents for cellular profiling and leads for developing enhanced and cell-permeable peptide or small-molecule inhibitors.
PubMed: 28594323
DOI: 10.7554/eLife.25541
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.346 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon